Hemogenyx shares jump on achieving POC for CBR platform

16 March 2022

UK-based biopharma Hemogenyx Pharmaceuticals (LSE: HEMO) has achieved proof of concept (POC) for its chimeric bait receptor (CBR) platform technology, news that sent its share price up by 9% in Wednesday morning’s trading.

The company has filed a seminal provisional patent application protecting its rights to the intellectual property covering CBR, a platform technology that Hemogenyx is confident ‘constitutes a new paradigm for treating viral infections’.

"A ground-breaking new approach to treat emerging viral infections and to potentially become an effective new form of cancer treatment"In essence, the CBR-based approach involves programming immune cells using a new type of modifiable synthetic receptor to destroy viral pathogens. This technique can also potentially be used to program immune cells to destroy malignant cells causing certain types of cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK